Product Suite
The MINI Neuropsychological Interview
The M.I.N.I. International Neuropsychiatric Interview (M.I.N.I. 6.0) is a short, structured diagnostic interview developed in 1990 by psychiatrists and clinicians in the United States and Europe for DSM-IV and ICD-10 psychiatric disorders. With an administration time of approximately 15 minutes, the M.I.N.I. 6.0 (10/10/10) is the structured psychiatric interview of choice for psychiatric evaluation and outcome tracking in clinical psychopharmacology trials and epidemiological studies. The M.I.N.I. is the most widely used psychiatric structured diagnostic interview instrument in the world, employed by mental health professionals and health organizations in more than 100 countries. View current customers.
Electronic Version of the Authors
The M.I.N.I. 6.0 (10/10/10) was created by David V. Sheehan, M.D., M.B.A., Professor of Psychiatry and Director of Psychiatric Research, University of South Florida College of Medicine, and Yves Lecrubier, M.D. Centre Hospitalier Sainte-Anne – Paris, France.
Validation
The M.I.N.I. has been validated against the much longer Structured Clinical Interview for DSM diagnoses (SCID-P) in English and French and against the Composite International Diagnostic Interview for ICD-10 (CIDI) in English, French and Arabic. It has also been validated against expert opinion in a large sample in four European countries (France, United Kingdom, Italy and Spain). According to researchers at the National Institute of Mental Health's (NIMH) Division of Clinical and Treatment Research, the M.I.N.I. is a fully validated and more time-efficient alternative to the SCID-P and CIDI.
Available Options
Please select from one of the following pricing options to view more information:
-
M.I.N.I. 6.0 for Students
-
M.I.N.I. 6.0 for Organizations (hospitals, governments, clinics, studies, clinical trials)
Sheehan Disability Scale (SDS)
The Sheehan Disability Scale (Sheehan 1983) is a composite of three self-rated items designed to measure the extent to which three major sectors in the patient’s life are impaired by panic, anxiety, phobic, or depressive symptoms. This scale has been used widely in psychopharmacology randomized controlled trials. This anchored visual analog scale uses visual-spatial, numeric, and verbal descriptive anchors simultaneously to assess disability across three domains: work, social life, and family life. The scale was thus designed because some people rate numerically (“he was 1.9 m tall”), others use verbal descriptive anchors (“he was very tall”), and still others communicate their rating spatio-visually (using their hands to point while commenting “he was this tall”). Some choose a combination of two or all three methods.
The Sheehan Disability Scale was developed as a treatment outcome measure that would be sensitive to change and to drug placebo differences over time. It may also be useful for identifying primary care patients with mental health-related functional impairment. It is not intended to substitute a comprehensive diagnostic procedure but rather to supplement symptom assessments.
SDS Overview
The patient rates the extent to which his or her 1) work, 2) social life or leisure activities, and 3) home life or family responsibilities are impaired by his or her symptoms on a 10-point visual analog scale. There are verbal descriptors for the points on the scale as well as numerical scores that provide more precise levels of the verbal descriptors. (Consequently, there are more numerical points than there are verbal descriptor anchors.) The Sheehan Disability Scale also provides a visual-spatial layout to accommodate those with spatial rating preferences. Example 8-7 provides items from the scale.
The numerical ratings of 0-10 can be translated into a percentage if desired. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). Typically 4 scores are derived from the scale in research studies- one for each of the work, social life and family life disability measures and an aggregate total score of these three scores combined. It is recommended that clinicians pay special attention to patients who score ?5 on any of the three scales, because such high scores are associated with significant functional impairment.
The scale may be used as a self-report, administered by a clinician, or rated by both independently. Because of this flexibility of administration, it is useful with both outpatients and inpatients. The scale is quite straightforward, and no scoring manual is necessary. It takes only 1-2 minutes to rate the scale.
Translations are available in 41 languages and in 36 dialects of 9 of these languages. In 32 of the 41 languages it is available in one form only. Altogether it is available in 66 languages or language dialect variants. View more language translation information.
SDS Reliability
In a study of 1,001 primary care patients, the inter-item correlations of the three Sheehan Disability Scale items were fairly high (0.70 for work and family impairment, 0.72 for work and social impairment, and 0.79 for family and social impairment). As a consequence of the strong relationships among the items, the internal consistency was also high (alpha = 0.89 for the three-item scale).
SDS Validity
In the study of 1,001 patients mentioned in the preceding section, the construct validity was substantiated in two ways. Overall, more than 80% of the patients with mental disorder diagnoses had an elevated Sheehan Disability Scale score, and nearly 50% of those with elevated scale scores had at least one disorder. Also, patients with any of six mental disorders (alcohol dependence, drug dependence, generalized anxiety disorder, major depressive disorder, obsessive-compulsive disorder, and panic disorder) had significantly higher impairment scores than those who did not have the disorders.
Validity was also indicated by the fact that the scores of subjects who reported “problems getting along with partner” were higher on both the family impairment item and the total score than the scores of subjects who denied having this type of problem. Likewise, those who reported “missing work in the past month due to emotional problems” had significantly higher scores on both the work impairment item and the total score.
An elevated Sheehan Disability Scale score (?5) was also found to be associated with increased risk of mental disorder. Using any of the six mental disorders listed earlier as the standard, the sensitivity (0.83), specificity (0.69), positive predictive value (0.47), and negative predictive value (0.92) were respectable for helping to identify psychiatrically impaired patients with the three-item scale.
The Sheehan Disability Scale appears to reflect change over time with effective treatment. In addition, it has been shown to discriminate between active drug and placebo and even between two active treatments.
Sheehan Suicidality Tracking Scale (S-STS)
Medical Outcomes Sheehan Suicidality Tracking Scale (S-STS) is an accurate assessment of treatment-emergent suicidal thoughts and behaviors, which is essential to both clinical care and randomized clinical trials. The Sheehan Suicidality Tracking Scale is a patient self-report or clinician-administered rating scale that tracks both treatment-emergent suicidal ideation and behaviors. The S-STS may also be a psychometric tool designed to be sensitive to change and to discriminate drug from placebo.
Medical Outcomes Sheehan Suicidality Tracking Scale maps to the FDA endorsed Columbia Classification Algorithm of Suicide Assessment (C-CASA) which was designed for retrospective classification of suicidal events.
The Sheehan-Suicidality Tracking Scale (S-STS) is a validated assessment of treatment-emergent suicidal thoughts and behaviors.
Sheehan-Suicidality Tracking Scale maps to the FDA endorsed Columbia Classification Algorithm of Suicide Assessment (C-CASA) which was designed for retrospective classification of suicidal events in the FDA guidance document of 2010 and 2012.
The Sheehan-Suicidality Tracking Scale is a patient self-report or clinician-administered rating scale that addresses all domains of suicidality and tracks both treatment-emergent suicidal ideation and behaviors.
The S-STS was designed to also be used as a psychometric tool designed to be sensitive to change and to discriminate drug from placebo.
Sheehan Homicidality Tracking Scale (S-HTS)
Overview: Accurate and prospective assessments of treatment-emergent suicidal thoughts and behaviors are essential to both clinical care and randomized clinical trials. The Sheehan Suicidality Tracking Scale is a prospective, patient self-report or clinician-administered rating scale that tracks both treatment-emergent suicidal ideation and behaviors. The Sheehan Suicidality Tracking Scale was incorporated into a multicenter, randomized, double-blind, placebo-controlled, and active comparator study examining the efficacy of an experimental corticotropin-releasing factor antagonist (BMS-562086) for the treatment of generalized anxiety disorder.
Results: A total of 82 subjects completed the Sheehan Suicidality Tracking Scale during the course of the study. Altogether, these subjects provided 297 completed Sheehan Suicidality Tracking Scale ratings across the study time points. Sixty-one subjects (n=25 placebo, n=24 BMS-562086, and n=12 escitalopram) had a baseline and at least one post-baseline Sheehan Suicidality Tracking Scale measurement. The mean change from baseline at Week 8 in the Sheehan Suicidality Tracking Scale total score was -0.10, -0.02, and -0.06 for escitalopram, placebo, and BMS-562086 groups, respectively. The sensitivity of the Sheehan Suicidality Tracking Scale and HAM-D Item #3 (suicide) for identifying subjects with suicidal thoughts or behaviors was 100 percent and 63 percent, respectively.
Conclusions: The Sheehan Suicidality Tracking Scale may be a sensitive psychometric tool to prospectively assess for treatment-emergent suicidal thoughts and behaviors. Despite the small sample size and low occurrence of suicidal ideation during the course of this clinical trial, the self-reported Sheehan Suicidality Tracking Scale demonstrated increased sensitivity over the rater administered HAM-D Item #3 in identifying suicide related ideations and behaviors. Further research in larger study samples as well as in other psychiatric disorders are needed.